The inhibitory action exerted by NPY on estradiol-stimulated growth of estrogen receptor-positive breast cancer cells was mediated by Y1R, and its expression could be used as a biomarker for survival/endocrine sensitivity in estrogen receptor-positive breast cancer patients [98]. Here, ESR1 is linked to breast carcinoma.